Patheon Launches SoluPath Flex™ Offering – The Customizable Solution to Rapidly Improve Solubility
Patheon, the pharmaceutical services business owned by DPx Holdings B.V., recently launched the SoluPath Flex™ offering, a new low solubility solution for the pharmaceutical industry.
This new offering allows customers to select from a full array of technologies and services to tailor a unique solution designed for each individual need, timeline and budget. With SoluPath Flex™ a wide-ranging list of solubility solutions can be completed in a single lab. And as the molecule progresses, the Patheon network then allows for a seamless transition to clinical trial and commercial supply, which saves time in development for the customers.
“SoluPath Flex™ allows our customers to partner with our scientific experts to determine the most effective and strategic ways to solve and overcome early development challenges related to solubility,” says Anil Kane, Ph.D., MBA, Executive Director, Global Head of Formulation Sciences, PDS, Patheon.
SoluPath Flex™ gives customers a simplified and customizable solution and the opportunity to work directly with a solubility expert from Patheon to define a solution to meet each unique requirement. All projects will be initiated and completed by a dedicated team working in a non-GMP lab within a GMP facility.
For additional information about SoluPath Flex™, please visit http://www.patheon.com/Services/UniqueSolutions/SoluPath.aspx.
Patheon
Tel: +1 (919) 226-3200
Email: media@patheon.com
About Patheon
Patheon is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Patheon, a DPx Holdings B.V. business unit, encompasses the combined CMO capabilities and pharmaceutical product development services (PDS), as well as the Biosolutions and Biologics (BIO) business. For more information visit http://www.patheon.com.
About DPx Holdings B.V.
DPx Holdings B.V. is the privately held parent company of the Patheon, DSM Fine Chemicals, and Banner Life Sciences businesses. The company is a leading provider of CDMO services, pharmaceutical products and products for other industries. Founded in 2014 as a result of a deal between JLL Partners and Royal DSM, DPx Holdings B.V. has three core business units, comprised of Patheon Pharma Services, DSM Fine Chemicals and Banner Life Sciences. With global headquarters in Durham, N.C., DPx Holdings B.V. has a footprint of 22 locations across North America, Europe, Latin America and Australia with more than 8,000 employees. DPx Holdings B.V. offers customers unsurpassed quality, integrated offerings and value through these three core business units. For more information visit www.patheon.com/DPx.